Search research articles
Contact Us
Filters
Showing results (21-30 of 72) with videos related to
Page
of 8
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Biomarkers
Vijaya L Reddy, Jesse M Cedarbaum, John Seibyl, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
May 1, 2020
A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease
Nurit Omer, Nir Giladi, Tanya Gurevich, et al.
European Journal of Neurology
|
May 14, 2024
Validity of the Short Weekly Calendar Planning Activity in patients with Parkinson disease and nonmanifesting LRRK2 and GBA carriers
Tamara Schejter-Margalit, Noam Ben Binyamin, Avner Thaler, et al.
Movement Disorders Clinical Practice
|
April 18, 2023
The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease
Jake DeBroff, Nurit Omer, Batsheva Cohen, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
November 12, 2014
Commonalities and challenges in the development of clinical trial measures in neurology
Jesse M Cedarbaum, Diane Stephenson, Richard Rudick, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
January 23, 2015
Erratum to: Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology
Jesse M Cedarbaum, Diane Stephenson, Richard Rudick, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
March 22, 2021
Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker
Rahul Gaurav, Lydia Yahia-Cherif, Nadya Pyatigorskaya, et al.
Journal of Neurology
|
January 3, 2021
Biochemical markers for severity and risk in GBA and LRRK2 Parkinson's disease
Avner Thaler, Nurit Omer, Nir Giladi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 24, 2009
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors
William P Tew, Michael Gordon, John Murren, et al.
Neuroimage. Clinical
|
September 7, 2018
FDG PET Parkinson's disease-related pattern as a biomarker for clinical trials in early stage disease
Dawn C Matthews, Hedva Lerman, Ana Lukic, et al.
Page
of 8
Search research articles
Search
Showing results (21-30 of 72) with videos related to
Sort By:
Page
of 8
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Biomarkers
Vijaya L Reddy, Jesse M Cedarbaum, John Seibyl, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
May 1, 2020
A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease
Nurit Omer, Nir Giladi, Tanya Gurevich, et al.
European Journal of Neurology
|
May 14, 2024
Validity of the Short Weekly Calendar Planning Activity in patients with Parkinson disease and nonmanifesting LRRK2 and GBA carriers
Tamara Schejter-Margalit, Noam Ben Binyamin, Avner Thaler, et al.
Movement Disorders Clinical Practice
|
April 18, 2023
The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease
Jake DeBroff, Nurit Omer, Batsheva Cohen, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
November 12, 2014
Commonalities and challenges in the development of clinical trial measures in neurology
Jesse M Cedarbaum, Diane Stephenson, Richard Rudick, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
January 23, 2015
Erratum to: Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology
Jesse M Cedarbaum, Diane Stephenson, Richard Rudick, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
March 22, 2021
Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker
Rahul Gaurav, Lydia Yahia-Cherif, Nadya Pyatigorskaya, et al.
Journal of Neurology
|
January 3, 2021
Biochemical markers for severity and risk in GBA and LRRK2 Parkinson's disease
Avner Thaler, Nurit Omer, Nir Giladi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 24, 2009
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors
William P Tew, Michael Gordon, John Murren, et al.
Neuroimage. Clinical
|
September 7, 2018
FDG PET Parkinson's disease-related pattern as a biomarker for clinical trials in early stage disease
Dawn C Matthews, Hedva Lerman, Ana Lukic, et al.
Page
of 8